BusinessReutersbloombergwsj+10FTcnbcglobe-and-mailmarketwatchmorningstarindex-hrYahoo20-minuten+2 more20h ago13 sources
Novartis Shares Plunge After Late-Stage Drug Trial Fails to Meet Targets
Novartis stock dropped sharply after the company reported that its late-stage trial for del-desiran failed to achieve its primary efficacy endpoints. The setback triggered a broader sell-off across the biopharmaceutical sector and raised concerns about the company’s development pipeline.